Nuvectis Pharma, Inc. (NVCT) Insider Trading & SEC Filings
Last SEC filing
Nuvectis Pharma, Inc. (NVCT) has filed 6 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-01. Insiders disclosed 2 open-market purchases totaling $1.17M. 4 Form 8-K material event filings were reported by NVCT in the last 90 days. InsiderAlpha tracks every NVCT SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. trades under the ticker NVCT. InsiderAlpha tracks 16 primary SEC Form 4 filings from 8 reporting insiders for NVCT since 2024, sourced directly from SEC EDGAR.
| SEC CIK | 0001875558 |
|---|
90-Day SEC Filing Activity
| Insider purchases (90d) | 2 ($1.17M) |
|---|---|
| Form 4 filings (90d) | 6 |
| Form 8-K filings (90d) | 4 |
| Latest Form 4 filing | 2026-07-01 |
Recent NVCT Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Ron Bentsur | Chairman & CEO | P - Open-market purchase | 12.5K | $20.00 | $250K | SEC | |
| Marlio Charles Mosseri | 10% Owner | P - Open-market purchase | 50.0K | $18.32 | $916K | SEC | |
| Kenneth Hoberman | Director | A - Grant or award | 35.0K | $0.00 | - | SEC | |
| Matthew L. Kaplan | Director | A - Grant or award | 35.0K | $0.00 | - | SEC | |
| Juan Sanchez | Director | A - Grant or award | 35.0K | $0.00 | - | SEC | |
| James F. Oliviero III | Director | A - Grant or award | 35.0K | $0.00 | - | SEC | |
| Ron Bentsur | Chairman & CEO | P - Open-market purchase | 5.0K | $5.72 | $29K | SEC | |
| Juan Sanchez | Director | P - Open-market purchase | 13.0K | $5.79 | $75K | SEC | |
| Matthew L. Kaplan | Director | P - Open-market purchase | 11.0K | $5.84 | $64K | SEC | |
| Marlio Charles Mosseri | 10% Owner | P - Open-market purchase | 72.8K | $6.28 | $457K | SEC | |
| Marlio Charles Mosseri | 10% Owner | P - Open-market purchase | 35.0K | $6.15 | $215K | SEC | |
| Marlio Charles Mosseri | 10% Owner | P - Open-market purchase | 46.9K | $6.06 | $284K | SEC | |
| Juan Sanchez | Director | A - Grant or award | 30.0K | $0.00 | - | SEC | |
| Ron Bentsur | Chairman & CEO | P - Open-market purchase | 4.5K | $4.65 | $21K | SEC | |
| Marlio Charles Mosseri | 10% Owner | P - Open-market purchase | 17.0K | $4.70 | $80K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Nuvectis Pharma, Inc. (NVCT). Updated in real time as new filings are submitted to the SEC.
Most-Active NVCT Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Kenneth Hoberman | 1 | - |
| Ron Bentsur | 1 | $250K |
| James F. Oliviero III | 1 | - |
| Marlio Charles Mosseri | 1 | $916K |
| Juan Sanchez | 1 | - |
Recent NVCT Form 8-K Material Events
- - Item 1.01, 8.01, 9.01 [SEC]
- - Item 8.01 [SEC]
- - Item 1.01, 8.01, 9.01 [SEC]
- - Item 5.07 [SEC]
- - Item 2.02, 9.01 [SEC]
Recent Insider Filings
- - Marlio Charles Mosseri (10% Owner)
- - Ron Bentsur (Chairman & CEO)
- - Kenneth Hoberman (Director)
- - James F. Oliviero III (Director)
- - Juan Sanchez (Director)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in NVCT insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
NVCT Insider Trading - FAQ
- What is the latest insider trade for NVCT?
- Nuvectis Pharma, Inc. (NVCT) had 6 insider filings in the last 90 days, with the most recent on 2026-07-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying NVCT stock?
- 2 insider purchases of NVCT were filed in the last 90 days, totaling $1.17M.
- How many insiders are selling NVCT stock?
- 0 insider sales of NVCT were filed in the last 90 days.
- Where can I see NVCT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks NVCT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $NWAX New America Acquisition I Corp.
- $NXB NextBoat Inc.
- $NXTS N2OFF, Inc.
- $NYB NYB Holdings Ltd
- $NZF Nuveen Municipal Credit Income Fund
- $OBAI TG-17, Inc.
- $OBTC Osprey Bitcoin Trust
- $OBX Gazelle Parent, Inc.
- $OCLT OceanLight Acquisition Corp
- $ODTX Odyssey Therapeutics, Inc.
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live NVCT dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.